MedTrace Logo

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2017-05-03

No results posted yet for this study

Summary

The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.

Conditions

  • Biomarkers, Pharmacological

Interventions

DRUG

Huperzine A

dosage form: tablet dose frequency: once only

DRUG

Donepezil

dosage form: tablet dosage frequency: once only

DRUG

Galantamine

dosage form: tablet dosage frequency: once only

OTHER

Placebo

dosage form: tablet dosage frequency: once only

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • MAJ James E Moon, MC · Walter Reed Army Institute of Research (WRAIR)

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194336 on ClinicalTrials.gov